All In Biotech

Free tool

FAERS Monitor: Cefotan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050588 or its brand name (Cefotan, Cefotetan Disodium). Reports on generic versions are filed under their own applications.

Reports

133

Serious

109

82% of reports

Hospitalization

68

Death reported

17

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • haemolytic anaemia20
  • nausea9
  • renal failure9
  • asthenia8
  • chronic kidney disease8
  • anaemia7
  • dizziness7
  • dyspnoea7
  • hypertension7
  • pain7
  • urticaria7
  • abdominal pain6
  • anxiety6
  • haemoglobin decreased6
  • injury6

Reports by year received

View as table
YearReports
200415
20058
200613
20073
20089
20098
20107
20119
20128
20133
20142
20159
20163
20174
20184
20194
20204
20216
20224
20238
20241
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,026 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemolytic anaemiaSignal20353.8236.16,676
chronic kidney diseaseSignal816.78.5103
injurySignal613.56.258
renal failureSignal910.75.770
haemoglobin decreasedSignal69.24.236
urticariaSignal76.63.228
anaemiaSignal75.82.823
hypertensionSignal75.22.520
abdominal painSignal64.11.911
astheniaSignal83.41.711
anxietySignal63.31.58
dizziness72.21.14
dyspnoea72.01.02
pain71.80.92
nausea91.81.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.